The notion that oncologists could boost immunotherapy responses simply by giving infusions in the morning, rather than late afternoon, is an attractive one. So when a clinical trial published in Nature Medicine this month showed that lung cancer patients treated in the morning had a massive reduction in the risk of progression compared to those treated in the afternoon, many scientists were intrigued, if skeptical.

Now that study is coming under fire, as multiple scientists and sleuths raise serious concerns about the data and point out inconsistencies in the trial.

These have called the study’s conclusions even further into question, which experts told STAT already lacked strong biological plausibility, and Nature Medicine appended a note on the study on Thursday that it is starting an investigation into the concerns.

Continue to STAT+ to read the full story…

A blood test for detecting cancer early being developed by the diagnostics firm Grail failed to meet its main goal in a giant study being conducted with England’s National Health Service, the company said Thursday.

Grail’s test has been the standard bearer for new technologies that promise a blood test can be used to detect many different types of cancer early and eventually even to indicate to scientists where in the body to look for tumors. The company already sells its test, called Galleri, for a list price of $1,000, although it is not yet approved by the Food and Drug Administration. Grail said Thursday it sold 185,000 tests in 2025, generating $136.8 million. 

The company’s shares were down 47% in after-hours trading.

Continue to STAT+ to read the full story…

In less than a year, new Medicaid eligibility restrictions may lead millions of people to lose coverage and then miss potentially lifesaving cancer screenings like colonoscopies or mammograms. A new analysis estimates that Americans may miss more than a million cancer screenings for colorectal, breast, or lung cancer over the two years after the new policy takes effect.

“I see patients every day that come to me with cancer and are asymptomatic, but their life gets turned upside down because they are told they have cancer,” said Adrian Diaz, a surgical oncologist at the University of Chicago and one of the authors on the paper, published Thursday in JAMA Oncology. “In a positive way, we catch it early. It’s potentially treatable, curable. Seeing that number, over a million patients, who will not have that opportunity — I was taken aback.”

Read the rest…